Language:
Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
labmedica.com
Clinical Chemistry
Features Subscription Partner Sites Journal Info
Veolia WATERRANDOX LABORATORIESAB Sciex

Inflammatory Biomarkers Predict Chronic Pulmonary Disease Outcome

By Labmedica International staff writers
Posted on 03 Apr 2012


Changes in inflammatory biomarkers establish clinical variables and improve the prediction of mortality in patients with chronic obstructive pulmonary disease (COPD).

COPD is characterized by low-grade systemic inflammation and the addition of inflammatory biomarker blood tests would establish predictive factors that will improve accuracy of a prognostic model for mortality.

An international multicenter team of scientists led by those at Brigham and Women’s Hospital (Boston, MA, USA) prospectively collected data on 1,843 COPD patients from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Of these 1,843 patients, 168 (9.1%) died during the three-year follow-up.

The biomarkers measured from serum samples were: Chemokine (C-C motif) ligand 18 (CCL-18 or pulmonary and activation-regulated chemokine, PARC), surfactant protein D (SP-D), interleukin 8 (IL-8), Clara cell secretory protein 16 (CC-16), and tumor necrosis factor alpha (TNFα). Fibrinogen and C-reactive protein (CRP using a high sensitivity method) were measured in plasma samples. All protein biomarkers were measured by validated immunoassays. Total white blood cells (WBC) and neutrophils were counted by an automated method.

The results of the study show that a panel of selected biomarkers, WBC counts, IL-6, fibrinogen, CCL-18, CRP, IL-8, and SP-D were not only elevated in nonsurvivors compared with survivors, but were also associated with mortality over three years after adjusting for clinical variables known to predict death in COPD. Bartolome M. Celli, MD, the lead author of the study, said, "Adding white blood cell counts and measurement of changes in systemic levels of IL-6, CRP, IL-8, fibrinogen, CCL-18, and SP-D significantly improves the ability of clinical variables to predict mortality in patients with COPD. This is the first study to show that the addition of biomarker levels to clinical predictors in COPD patients adds relevant prognostic information." The study was published on March 23, 2012, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:
Brigham and Women’s Hospital





Monoclonal Antibodies
Monoclonal Antibodies
Gastrointestinal Assays
Gastrointestinal Assays
Handheld Biosensor
Handheld Biosensor

More Products

ADVANCED INSTRUMENTS

Latest Clinical Chemistry News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Whitepaper
EKF Diagnostics:
Diabetes Management in a Point of Care Setting

Download Whitepaper
Events
ESHRE 2013 – 29th Annual Meeting of the European Society for Human Reproduction and Embryology
07 Jul 2013 - 10 Jul 2013


26th Annual Meeting of the Association of Medical Laboratory Immunologists (AMLI)
10 Aug 2013 - 13 Aug 2013


ISEH 42ND Annual Scientific Meeting
22 Aug 2013 - 25 Aug 2013


More events
GLOBETECH PUBLISHING
Latest Issue

View Digital Edition
Subscribe / Renew
KARL HECHT GMBH & CO KG
77 ELEKTRONIKA
EUROIMMUN AG
EKF Diagnostics
BioPorto Diagnostics
GREINER-BIO-ONE
  labmedica.com Copyright © 2000-2013 Globetech Media. All rights reserved.
Privacy Policy